HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study.

Xinya YeXiaoqing ChenHan LiuYichao JiangChengyu YangTao XuZiyou ChenYalin WangFentian ChenXue LiuHai YuQuan YuanNingshao XiaYuanzhi ChenWenxin Luo

Published in: Antibody therapeutics (2024)

HBV-neutralizing antibody 129G1 was linked with a TLR7/8 agonist small molecule compound IMDQ.Treatment with 129G1-IMDQ has shown significant promise in lowering HBsAg levels in AAV/HBV mice.129G1-IMDQ were eliciting a strong and lasting anti-HBsAg immune response after short-term treatment in AAV/HBV mice.

Keyphrases

hepatitis b virus
immune response
liver failure
small molecule
toll like receptor
high fat diet induced
inflammatory response
gene therapy
type diabetes
cancer therapy
machine learning
metabolic syndrome
wild type
combination therapy
artificial intelligence
deep learning
dengue virus
replacement therapy